FindTrial
Sign In

Observation on the Efficacy of Cyclosporine in the Treatment of Patients with Atopic Dermatitis Involving the Hands and Feet

Observation on the Efficacy of Cyclosporine in the Treatment of Patients with Atopic Dermatitis Involving the Hands and Feet

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600128389
Enrollment
Unknown
Registered
2026-07-20
Start date
2026-07-20
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Interventions

Ciclosporin group:None

Sponsors

The First Affiliated Hospital of Guilin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Patients who meet the Chinese diagnostic criteria for atopic dermatitis as defined in the Chinese Guidelines for the Diagnosis and Treatment of Atopic Dermatitis (2020 Edition); 2.Affected sites include the hands and feet; 3.Age >= 18 years at the baseline visit, with no gender restriction; 4.Inadequately controlled with oral antihistamines and topical medications; 5.Voluntary participation in the study and signing of the written informed consent form.

Exclusion criteria

Exclusion criteria: 1.Hypersensitivity to the active ingredient of ciclosporin; 2.Pregnant or breastfeeding women; 3.Patients currently participating in or planning to participate in other interventional studies during the study period; 4.Any disease that, in the investigator's opinion, may interfere with the patient's participation in the study, such as: concomitant hepatic or renal insufficiency; active infection; uncontrolled hypertension; coexisting malignancy or severe organic disease; or other comorbidities that could foreseeably affect the patient's ability to complete scheduled visits and assessments; 5.Other factors that, in the investigator's opinion, make the patient unsuitable for participation in the study.

Design outcomes

Primary

MeasureTime frame
Proportion of patients achieving EASI 75 and HECSI-75 at 8 weeks;—

Secondary

MeasureTime frame
Changes from baseline in SCORAD, DLQI, ADCT, PP?NRS, BSA, and HECSI scores;Proportion of patients achieving EASI 75 at weeks 2, 4, and 12;proportion of patients achieving ESAI 90 at weeks 2, 4, 8, and 12;Proportion of patients achieving IGA 0/1 at week 12;Changes in serum eosinophil count and serum total IgE levels;—

Countries

China

Contacts

Public ContactChen Fangru

The First Affiliated Hospital of Guilin Medical University

7339102@qq.com+86 773 2823796

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026